Clinical Research Directory

Inclusion Criteria: 1. Written informed consent was signed before the implementation of any test-related procedures ; 2. Age 18-75 years ; 3. Esophageal squamous cell carcinoma confirmed by histopathology ; 4. Resectable thoracic cT1b-2N1-3M0 or cT2-3N0M0 ; 5. No anti-tumor treatment has been received ; 6. ECOG PS 0-1 ; 7. Expected survival ≥ 3 months ; 8. At least one measurable lesion per RECIST v1.1; 9. Adequate organ function (hematology, liver, kidney, coagulation, thyroid, myocardial enzymes) ; 10. For women of childbearing age, a negative urine or serum pregnancy test should be performed within three days prior to the first study drug administration ( day 1 of the first cycle ). If the urine pregnancy test results cannot be confirmed as negative, a blood pregnancy test is required. Women of non-fertility age were defined as at least 1 year after menopause, or had undergone surgical sterilization or hysterectomy ; 11. If there is a risk of conception, all subjects ( male or female ) are required to use contraception with an annual failure rate of less than 1 % throughout the treatment period up to 120 days after the last study drug administration ( or 180 days after the last study drug administration ). Exclusion Criteria: 1. High risk of tracheoesophageal fistula or aortoesophageal fistula 2. Prior radiotherapy, chemotherapy, targeted therapy, or immunotherapy 3. Participation in another interventional clinical trial within 4 weeks before the first dose 4. History of other active malignancies (except cured low-risk tumors, adequately treated non-melanoma skin cancer, or carcinoma in situ) 5. Active uncontrolled hepatitis B/C infection 6. Uncontrolled systemic diseases (e.g., heart failure NYHA ≥II, interstitial lung disease, active autoimmune diseases requiring systemic immunosuppression) 7. Allergy to study drugs or excipients 8. Uncontrolled third-space effusion (e.g., pleural/pericardial effusion) 9. Pregnant or lactating women